Alumis Inc. (NASDAQ:ALMS) Receives Average Rating of “Buy” from Brokerages

Shares of Alumis Inc. (NASDAQ:ALMS) have been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $26.83.

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $26.00 target price on shares of Alumis in a report on Friday, December 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Robert W. Baird started coverage on Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 target price on the stock. Finally, Baird R W upgraded Alumis to a “strong-buy” rating in a report on Thursday, October 31st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in Alumis in the third quarter worth $27,000. MetLife Investment Management LLC bought a new stake in shares of Alumis during the 3rd quarter valued at $89,000. JPMorgan Chase & Co. purchased a new stake in shares of Alumis in the 3rd quarter worth about $191,000. Barclays PLC bought a new position in shares of Alumis in the 3rd quarter worth about $197,000. Finally, Maven Securities LTD purchased a new position in Alumis during the 2nd quarter valued at about $332,000.

Alumis Stock Performance

Shares of Alumis stock opened at $7.52 on Tuesday. The stock has a fifty day moving average price of $9.81. Alumis has a 12-month low of $7.46 and a 12-month high of $13.53.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.